Haematology

Victoria Potter image

Dr Victoria Potter

Consultant Haematologist
Qualifications:

BSc, MBBS (hons) FRACP, FRCPA

Year qualified:

2000

Primary speciality:

Haematology

Specialist interests:
  1. Allogeneic stem cell transplantation
  2. Myeloid disorders including myelodysplastic syndrome and AML
  3. CAR-T therapy
Professional memberships:
  • Royal Australasian College of Physicians
  • Royal College of Pathologists of Australasia
  • European Society of Blood and Marrow Transplantation
  • British Society of Blood and Marrow Transplantation
PA name:

Carol Whittington

Telephone:

+44 (0)20 3299 5065

Consulting address:

Guthrie Clinic
King's College Hospital
NHS Foundation Trust
Denmark Hill
London SE5 9RS

Clinic times:

By Appointment

Biography

Dr Victoria Potter is a consultant haematologist specialising in stem cell transplantation at Kings College Hospital, London. After graduating from the University of Sydney she completed early post-graduate and specialty training in haematology in Sydney, Australia, working at Westmead, Prince of Wales and St Vincent’s Hospitals. In 2010 she moved to London to take up a clinical fellowship position at Kings before accepting a consultant position in myeloid malignancies and transplantation. During this time she participated in the visiting physicians programme at Fred Hutchinson Cancer Centre Seattle. In November 2017, Victoria was appointed BMT Director at Kings College Hospital. She is a member of the CMWP of the EBMT and is committed to the development of clinical trials in transplantation. She is the IMPACT principal investigator for Kings College Hospital London and the current secretary of the BSBMT clinical trials committee. Her research interests focus on the use of DLI for the prevention of relapse post-transplant.

Dr Potter is fully trained in the assessment of patients for, and delivery of, CAR-T therapy, a highly specialised new therapy that has recently been licenced for certain patients with relapsed high grade B cell lymphomas and acute lymphoblastic leukaemia. She is active in the development of an early trial for the delivery of allogeneic CAR-T therapy in acute myeloid leukaemia.

2016 - 2019 © King's College Hospital NHS Foundation Trust